Aprea Therapeutics Reports Q3 GAAP EPS of -$0.09 in Line with Expectations
Aprea Therapeutics (APRE) has reported its third-quarter financial results, announcing a GAAP earnings per share (EPS) of -$0.09, which met market expectations. The report highlights the company's current liquidity position as it continues its clinical operations. As of September 30, 2026, the company reported cash and cash equivalents totaling $37.8 million. This represents a significant increase from the $14.6 million held as of December 31, 2025, providing a strengthened capital cushion for upcoming operational requirements.
Topics: cash_position earnings financial_results